Influenza and Other Respiratory Viruses最新文献

The Global Initiative on Sharing All Influenza Data, a public-access database for sharing severe acute respiratory syndrome coronavirus 2 genomic sequencing data, has received significantly less data from African countries compared to the global total. Furthermore, the contribution of these data was infrequent and, for some countries, non-existent. The primary aim of this review is to identify the technological barriers to routine genomic surveillance in Africa. PubMed and Google Scholar were searched for the relevant articles, and other eligible articles were identified from the reference list examination according to the PRISMA checklist. Eighty-four full-text articles were analysed for eligibility, and 49 published full-texted articles were included in the final qualitative analysis. The main technological barriers identified were limited genomic surveillance capacity, limited genomic sequencing infrastructure, lack of resources and skilled or trained scientists, and the high cost of importing, establishing, and maintaining a genomic sequencing facility. The Africa Pathogen Genomics Initiative aims to improve genomic surveillance capacity across Africa, through resources, training, education, infrastructure, and regional sequencing centres. Furthermore, collaborations between African governments and international partners or national, private, and academic institutions are imperative to sustain genomic surveillance in Africa, and investment in genomic sequencing and research and development is paramount. Longer turnaround times interfere with global viral evolution monitoring and national implementation of effective policies to reduce the burden and disease. Establishing effective genomic surveillance systems guides public health responses and vaccine development for diseases endemic in Africa.

Mazagatos, C., Mendioroz, J., Rumayor, M., Gallardo García, V., Álvarez Río, V., Cebollada Gracia, A., Batalla Rebollo, N., Barranco Boada, M., Pérez-Martínez, O., Lameiras Azevedo, A., López González-Coviella, N., Castrillejo, D., Fernández Ibáñez, A., Giménez Duran, J., Ramírez Córcoles, C., Ramos Marín, V., Larrauri, A., Monge, S. and (2024), Estimated Impact of Nirsevimab on the Incidence of Respiratory Syncytial Virus Infections Requiring Hospital Admission in Children < 1 Year, Weeks 40, 2023, to 8, 2024, Spain. Influenza Other Respi Viruses, 18: e13294. https://doi.org/10.1111/irv.13294

In the article, there was an error in the denominators reported by one of the regions contributing to the national SiVIRA surveillance, affecting both the primary care and hospital catchment populations. This error affects the calculation of national SARI hospitalisation rates for the 2022–2023 and 2023–2024 seasons, as well as all subsequent estimates of RSV-specific proxy hospitalisation rates and the observed and expected number of RSV hospitalisations. Although Figures 1 and 2 and the published estimates in Table 1 have changed, this correction does not change the overall study conclusions.

The corrected Table 1 is as follows:

The corrected Figures 1 and 2 are as follows:

The text should be corrected every time these estimates are mentioned: In Section 2.3, ‘Estimated Impact of Nirsevimab: Comparing Observed and Expected’, the text in the second paragraph ‘We estimated that, during weeks 40/2023 to 8/2024, the administration of nirsevimab reduced RSV hospitalisations in < 1-year-olds by between 74% and 75%, depending on the scaling factor used. This resulted in between 9364 and 9875 averted RSV hospitalisations in this group and period’ was incorrect and should read as ‘We estimated that, during weeks 40/2023 to 8/2024, the administration of nirsevimab reduced RSV hospitalisations in < 1-year-olds by between 71% and 77%, depending on the scaling factor used. This resulted in between 7510 and 10,213 averted RSV hospitalisations in this group and period’.

In the discussion section, fourth paragraph, the text ‘Our study has estimated a 74%–75% relative reduction in the risk of RSV hospitalisation …’ was incorrect and should read as ‘Our study has estimated a 71%–77% relative reduction in the risk of RSV hospitalisation …’.

We apologise for this error.

We estimated XBB.1.5 vaccine effectiveness (VE) against symptomatic SARS-CoV-2 infection among adults aged ≥ 65 years during the 2023/2024 JN.1 lineage-predominant period in a European multi-country test-negative case–control study at primary care level. We estimated VE adjusted by study site, age, sex, chronic conditions and onset date. We included 220 cases and 1733 controls. The VE was 48% (95% CI: 12–71), 23% (95% CI: −11–48) and 5% (95% CI: −92–56) among those with symptom onset 1–5, 6–11, and ≥ 12 weeks after vaccination, respectively. XBB.1.5 vaccine provided short and moderate protection against JN.1 symptomatic infection.